According to the ETF Finder at ETF Channel, ALNY makes up 2.24% of the SPDR S&P Biotech ETF (XBI) which is lower by about 0.2% on the day Friday.
In afternoon trading Friday, ALNY was down about 0.2% on the day.
Alnylam Pharmaceuticals' (ALNY) phase III trial for its patisiran drug was recommended to continue by the trial's data monitoring committee.
Alnylam Pharmaceuticals (ALNY) ended production of a key drug yesterday, prompting Morgan Stanley to cut its rating on the stock earlier today.
Here are Friday's top research calls, including downgrades for Fifth Third and Alnylam, an upgrade for Gap and new coverage of Advanced Micro Devices.
Stocks stay close to the flatline on Thursday as Wall Street waits for the release of the monthly U.S. jobs report on Friday.